S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
Log in

Arena Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:ARNA)

$46.90
+0.59 (+1.27 %)
(As of 11/21/2019 04:00 PM ET)
Today's Range
$45.68
Now: $46.90
$46.95
50-Day Range
$44.69
MA: $47.60
$50.03
52-Week Range
$35.04
Now: $46.90
$64.48
Volume390,300 shs
Average Volume464,707 shs
Market Capitalization$2.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Arena Pharmaceuticals, Inc, a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.97 million
Book Value$12.27 per share

Profitability

Net Income$-29,400,000.00

Miscellaneous

Employees194
Market Cap$2.35 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.


Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals shares reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.32) by $0.14. The biopharmaceutical company had revenue of $1.35 million for the quarter, compared to analysts' expectations of $2.06 million. Arena Pharmaceuticals had a return on equity of 42.34% and a net margin of 68.29%. The firm's revenue for the quarter was down 62.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.70) EPS. View Arena Pharmaceuticals' Earnings History.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Arena Pharmaceuticals.

What price target have analysts set for ARNA?

7 analysts have issued 12 month price objectives for Arena Pharmaceuticals' shares. Their forecasts range from $51.00 to $79.00. On average, they anticipate Arena Pharmaceuticals' stock price to reach $63.67 in the next twelve months. This suggests a possible upside of 35.7% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals.

What is the consensus analysts' recommendation for Arena Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Arena Pharmaceuticals reported impressive first-quarter results wherein earnings and sales surpassed the respective estimates. The company is focused on developing its two pipeline candidates – etrasimod and olorinab. The company out-licensed ralinepag to United Therapeutics and the fund is being used to support continuation of clinical development of other candidates. Meanwhile, the company’s decision to sell its manufacturing operations to focus on the pipeline is prudent, in our view. However, Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have a negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in a competitive market. Shares of the company have outperformed the industry so far this year." (5/15/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $62 PT. Arena today reported 1Q financials and provided an update on its clinical programs, including details on the etrasimod Ph3 trial design in ulcerative colitis (UC) that is still expected to initiate mid-year. We think the planned Ph3 UC program is strategically designed to expedite enrollment and support a differentiated commercial profile for etrasimod. We continue to believe IBD represents a large and growing market, and etrasimod is well-positioned in UC with potential to expand into other I&I indications due to its safety profile." (5/8/2019)

Has Arena Pharmaceuticals been receiving favorable news coverage?

Media headlines about ARNA stock have trended somewhat negative on Thursday, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Arena Pharmaceuticals.

Are investors shorting Arena Pharmaceuticals?

Arena Pharmaceuticals saw a drop in short interest during the month of October. As of October 15th, there was short interest totalling 2,840,000 shares, a drop of 11.5% from the September 15th total of 3,210,000 shares. Based on an average daily volume of 442,800 shares, the short-interest ratio is presently 6.4 days. Approximately 5.8% of the shares of the stock are sold short. View Arena Pharmaceuticals' Current Options Chain.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Cytokinetics (CYTK), Advanced Micro Devices (AMD), Canopy Growth (CGC), Micron Technology (MU), Inovio Pharmaceuticals (INO), XOMA (XOMA), ZIOPHARM Oncology (ZIOP), Zynerba Pharmaceuticals (ZYNE), NVIDIA (NVDA) and Exelixis (EXEL).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:
  • Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
  • Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
  • Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 51)
  • Dr. Preston S. Klassen, Exec. VP of R&D and Chief Medical Officer (Age 50)

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Eagle Asset Management Inc. (1.90%), Emerald Advisers LLC (0.58%), Emerald Mutual Fund Advisers Trust (0.57%), Rhenman & Partners Asset Management AB (0.31%), California Public Employees Retirement System (0.22%) and Alps Advisors Inc. (0.21%). Company insiders that own Arena Pharmaceuticals stock include Jayson Donald Alexander Dallas, Preston Klassen, Randall E Woods, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Institutional Ownership Trends for Arena Pharmaceuticals.

Which institutional investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Rhenman & Partners Asset Management AB, Systematic Financial Management LP, Mackay Shields LLC, Commonwealth Equity Services LLC and Exane Derivatives. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Jayson Donald Alexander Dallas, Preston Klassen, Randall E Woods, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Insider Buying and Selling for Arena Pharmaceuticals.

Which institutional investors are buying Arena Pharmaceuticals stock?

ARNA stock was purchased by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Sepio Capital LLC, Handelsbanken Fonder AB, First Trust Advisors LP, California Public Employees Retirement System, State of New Jersey Common Pension Fund D, SG Americas Securities LLC and Hussman Strategic Advisors Inc.. View Insider Buying and Selling for Arena Pharmaceuticals.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $46.90.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $2.35 billion and generates $17.97 million in revenue each year. The biopharmaceutical company earns $-29,400,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.View Additional Information About Arena Pharmaceuticals.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is http://www.arenapharm.com/.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]


MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  360 (Vote Outperform)
Underperform Votes:  405 (Vote Underperform)
Total Votes:  765
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel